Senator Elizabeth Warren, D-Massachusetts, has introduced a bill in the Senate that would create an Office of Drug Manufacturing within HHS. Simultaneously, Representative Jan Schakowsky, D-Illinois, introduced an identical bill in the House of Representatives.
Senator Elizabeth Warren, D-Massachusetts, has introduced a bill in the Senate that would create an Office of Drug Manufacturing within HHS. Simultaneously, Representative Jan Schakowsky, D-Illinois, introduced an identical bill in the House of Representatives.
Warren’s bill, dubbed the Affordable Drug Manufacturing Act, would require HHS to publicly manufacture generic drugs “in cases where the market has failed,” and “[strengthen] the market for the long term by jump-starting competition.”
Specifically, the office would be authorized to manufacture a generic drug in a case in which no company is currently manufacturing the product; a case in which only 1 or 2 companies produce the drug, and the price has spiked or the drug is in shortage; or a case in which only 1 or 2 companies produce the drug, the price has created a barrier to patient access, and the World Health Organization has designated the medication as an essential medicine.
“In market after market, competition is dying as a handful of giant companies spend millions to rig the rules, insulate themselves from accountability, and line their pockets at the expense of American families,” said Warren in a statement. “The solution here is not to replace markets, but to fix them. The Affordable Drug Manufacturing Act will introduce more competition into the prescription drug market and bring down prices for consumers.”
The price of insulin has entered the spotlight recently as it is becoming increasingly less affordable, particularly for young adults. Since 2012, the price has more than doubled in the United States. The bill would attempt to address this by requiring the office to begin public production of insulin within 1 year.
Within 1 year of the bill’s enactment, the office will be required to manufacture at least 15 applicable drugs. Additionally, no later than 3 years after the bill is enacted, the office will be required to manufacture or enter into contracts with entities for the manufacturing of at least 25 applicable products.
The introduction of the bill comes on the heels of a letter sent by Warren to Republican colleagues calling for hearings on the recent reports of alleged price-fixing by generic manufacturers in the start of January 2019.
Budget Impact Analysis of Biosimilar Natalizumab in the US
Projected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Biosimilars Policy Roundup for April 2024—Podcast Edition
May 5th 2024On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from April, including 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of Biologics USA conference.
Hesitancy in MENA Nations to Adopt WHO Biosimilar Guidelines Hinders Market Development
July 17th 2024The World Health Organization’s (WHO) new guidelines for biosimilar approvals aim to save time and money for manufacturers in the Middle East and North Africa (MENA), but hesitancy among nations to adopt the guidelines is stifling market development of biosimilars.
BioRationality: Time to Get Rid of PBMs if Biosimilars Are to Succeed
July 15th 2024Sarfaraz K. Niazi, PhD, discusses the challenges with pharmacy benefit managers (PBMs) that plague the biosimilar industry and new legislation that attempts to reform their practices and encourage biosimilar adoption.